On August 26, 2026, Japan’s patent office and all ten ASEAN intellectual property offices agreed to a new bilateral action plan built on a claim of “growing convergence” in patent examination standards. The research the agreement itself cites tells a more divided story: Indonesia opened a domestic biological-material depository in February 2026, while Vietnam, five years after joining the treaty that governs those deposits, still has none.

What did the August 26 meeting actually agree to?

The Japan Patent Office (JPO) and the intellectual property offices of the ten ASEAN Member States held the 16th ASEAN-Japan Heads of IP Offices Meeting in Singapore on August 26, 2026, according to the JPO. There, they adopted the ASEAN-Japan Intellectual Property Action Plan 2026–2027 and heard reports from the Economic Research Institute for ASEAN and East Asia (ERIA), a Jakarta-based policy institute that conducts research for ASEAN, Japan, and six other East Asian economies. The JPO also held separate bilateral sessions with Indonesia, Malaysia, Denmark, the Philippines, Thailand, Laos, Singapore, and Cambodia to confirm continued cooperation.

One of ERIA’s reports was the final output of a two-year, two-phase study on pharmaceutical patent examination practice across ASEAN, launched in 2024 and completed at a Tokyo workshop in July 2025 covering Brunei, Cambodia, Myanmar, and Vietnam — added to six member states studied in Phase 1. Its headline finding, per ERIA: “converging standards on patentability criteria… though variations remain in interpretation and application.”

What variation does “convergence” skip past?

One of those variations is not a matter of interpretation. It is Vietnam’s absence, five years into treaty membership, of a domestic authority for depositing microorganisms in a patent application. Vietnam acceded to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure on June 1, 2021, one of the commitments made under the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), according to Lexology and the Vietnamese IP firm InvestIP. The treaty lets an applicant deposit a biological sample — a bacterial strain, a fungal culture, a cell line — at any recognized International Depositary Authority (IDA) and have every other member state’s patent office accept it without a second deposit. As of January 2026, 92 countries carry that obligation, according to the World Intellectual Property Organization (WIPO).

What Vietnam has never done is build an IDA of its own. Indonesia has: the Indonesian Culture Collection (InaCC) formally acquired IDA status on February 24, 2026, per WIPO’s treaty notification registry — giving Indonesian applicants, for the first time, a domestic option instead of shipping a live culture to a depository in Japan, the United States, or Europe and waiting for it to clear customs, survive transit, and be accepted before a filing clock can even start.

What does the gap cost a licensing deal, not just a filing?

For a biotech or agricultural-genetics licensor working an ASEAN deal, this isn’t academic. A patent claim resting on a microorganism deposit is unenforceable until the deposit is made and accepted — and every extra week a sample spends in transit to a foreign IDA is a week the priority date, the licensing timeline, and the freedom-to-operate opinion a counterparty is waiting on all sit exposed.

Cambodia and Myanmar carry a separate but related risk ERIA flagged in the same report: limited examiner capacity to apply even the standards that already exist on paper. That’s a resourcing gap rather than a legal one, but it shows up in the same place a depository gap does — how far a counterparty can trust a pending claim to actually issue, and issue on schedule.

None of this appears in the language both sides used to describe August 26. “Converging” is accurate for patentability criteria on paper. It is not yet accurate for the physical infrastructure a biological-material claim depends on to be filed at all.

What should a licensing team check before the next filing?

A licensing or tech-transfer team moving a biological-material claim through ASEAN this quarter should confirm, before signing, which member state’s application it’s filing into and whether that state operates its own IDA or requires a foreign deposit — Vietnam, Cambodia, Laos, and Myanmar currently sit in the latter group. Build the shipping and acceptance lag into the licensing timeline rather than assuming the priority date locks in the moment the application is filed. And where a deal’s value depends on enforceability in Cambodia or Myanmar specifically, price in the examiner-capacity risk ERIA flagged: a granted claim there currently rests on a thinner review than the same claim gets in Singapore or Indonesia.

Key takeaways

  • Japan and all ten ASEAN IP offices adopted the ASEAN-Japan Intellectual Property Action Plan 2026–2027 at a Singapore meeting on August 26, 2026, describing patent examination standards as converging.
  • The ERIA research underlying that meeting found Vietnam still has no domestic depositary authority for microorganisms, five years after acceding to the Budapest Treaty on June 1, 2021.
  • Indonesia’s Indonesian Culture Collection (InaCC) became a recognized International Depositary Authority on February 24, 2026, giving it capacity Vietnam still lacks.
  • Cambodia and Myanmar face a separate constraint ERIA identified: limited patent-examiner capacity to apply the standards it describes as converging on paper.
  • Licensing and tech-transfer teams should confirm domestic IDA availability and build shipping and acceptance lag into filing timelines before relying on a microorganism-dependent claim in Vietnam, Cambodia, Laos, or Myanmar.